新辅助免疫检查点阻断在可切除的非小细胞肺癌中的前景和局限性。
The Promise and Limitations of Neoadjuvant Immune-Checkpoint Blockade in Resectable Non-Small Cell Lung Cancer.
发表日期：2023 Nov 01
作者：
Alissa J Cooper, Helena A Yu
来源：
Cancer Discovery
摘要：
可切除非小细胞肺癌的新辅助免疫检查点阻断已成为临床和转化探索的一个令人兴奋的领域。 Cascone 及其同事提出了一项在手术切除前对新型免疫调节剂进行一个周期的平台研究，为进行转化生物标志物研究提供了独特的机会，尽管关于最终应用于更广泛患者群体的问题仍然存在。请参阅 Cascone 等人的相关文章，第 17 页。 2394 (1).©2023 美国癌症研究协会。
The landscape of neoadjuvant immune-checkpoint blockade for resectable non-small cell lung cancer has become an exciting area of clinical and translational exploration. Cascone and colleagues present a platform study of one cycle of novel immunomodulatory agents prior to surgical resection, offering a unique opportunity to perform translational biomarker studies, though many questions remain regarding the ultimate application to a broader patient population. See related article by Cascone et al., p. 2394 (1).©2023 American Association for Cancer Research.